<DOC>
	<DOCNO>NCT02745353</DOCNO>
	<brief_summary>The purpose study compare effect naloxegol versus patient 's usual care treat opioid-induced constipation , well effect patient 's quality life much pain experience . Also , purpose study compare whether treatment naloxegol versus usual care impact number hospital clinic visit telephone call patient 's physician related constipation , determine patient 's preference continue receive naloxegol treatment opioid-induced constipation .</brief_summary>
	<brief_title>Naloxegol Cancer Opioid-Induced Constipation</brief_title>
	<detailed_description>Opioid-induced constipation ( OIC ) common symptom patient cancer-related pain require burdensome self-titration laxative prophylaxis treatment . Consequently , naloxegol may important role setting . Naloxegol evaluate relieve OIC cancer patient randomize , double blind , placebo-controlled trial 4 week 12-week extension phase . However , accrual challenge trial close early . Given complexity cancer treatment , key first step determine evaluate naloxegol versus standard care feasible management OIC setting . Subjects receive naloxegol 25mg daily usual care 2-week initial treatment period follow 3-day washout period , 2-week crossover treatment period subject receive naloxegol usual care . Treatment assignment initial crossover treatment period dictate randomization arm . Subjects also option participate 12-week extension phase naloxegol .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Naloxegol</mesh_term>
	<criteria>Adults great equal 18 year old . Eastern Cooperative Oncology Group ( ECOG ) less equal 3 . Glomerular filtration rate ( GFR ) great equal 30 ml/min/1.73m2 Modification Diet Renal Disease ( MDRD ) . Corrected serum calcium level less equal 10.5 mg/dL . Estimated life expectancy great equal 6 month . Negative pregnancy test prior initiate study treatment female childbearing potential . Patients receive follow medication within 3 day Study Day 1 and/or plan receive throughout duration study period : opioid antagonist , mixed antagonist , strong CYP3A4 and/or Pglycoprotein ( Pgp ) inhibitor , moderate CYP3A4 and/or Pgp inhibitor , and/or strong CYP3A4 inducer . Concurrent total parenteral nutrition and/or use metoclopramide . Patients high risk bowel perforation . Constipation primarily cause opioids investigator 's medical opinion . A condition may affect permeability bloodbrain barrier ( e.g. , know brain metastasis , meningeal metastasis , brain injury , multiple sclerosis , recent brain injury , uncontrolled epilepsy ) Patient clinically active diverticular disease . Past medical history irritable bowel syndrome , sign active gastrointestinal ( GI ) bleeding , acute surgical abdomen , bowel stent , indwell peritoneal catheter , mechanical GI obstruction , fecal impaction , fecal ostomy . Patient motility/neurologic disorder include autonomic failure ( spinal cord lesion , tumor invasion nerve ) and/or poorly control endocrine/metabolic disorder ( hypercalcemia , hypokalemia , diabetes , hypothyroidism ) , determine investigator . Uncontrolled cancer pain despite analgesic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Constipation</keyword>
	<keyword>Opioid</keyword>
</DOC>